A Phase 1 Open-label Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Brief description of study

The purpose of the study is to evaluate how your body tolerates IGM-2323, the safety of IGM-2323, and how IGM-2323 is taken up by your body when administered intravenously (IV) at different dose levels over the course of the study. IGM-2323 is a new type of engineered antibody. IGM-2323 is a bispecific antibody, which binds to 2 different targets, in this case 2 different cell types. The study drug IGM-2323 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial for the treatment of Non-Hodgkin Lymphoma.


Clinical Study Identifier: s19-01845
ClinicalTrials.gov Identifier: NCT04082936
Principal Investigator: Catherine M Diefenbach.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.